Celldex Therapeutics Cash on Hand 2010-2022 | CLDX

Celldex Therapeutics cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Celldex Therapeutics Annual Cash on Hand
(Millions of US $)
2021 $408
2020 $194
2019 $64
2018 $94
2017 $139
2016 $190
2015 $290
2014 $201
2013 $303
2012 $84
2011 $53
2010 $61
2009 $82
Celldex Therapeutics Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $380
2021-12-31 $408
2021-09-30 $423
2021-06-30 $164
2021-03-31 $176
2020-12-31 $194
2020-09-30 $200
2020-06-30 $207
2020-03-31 $54
2019-12-31 $64
2019-09-30 $73
2019-06-30 $81
2019-03-31 $85
2018-12-31 $94
2018-09-30 $106
2018-06-30 $114
2018-03-31 $123
2017-12-31 $139
2017-09-30 $141
2017-06-30 $154
2017-03-31 $167
2016-12-31 $190
2016-09-30 $203
2016-06-30 $220
2016-03-31 $254
2015-12-31 $290
2015-09-30 $305
2015-06-30 $334
2015-03-31 $360
2014-12-31 $201
2014-09-30 $224
2014-06-30 $252
2014-03-31 $274
2013-12-31 $303
2013-09-30 $137
2013-06-30 $155
2013-03-31 $182
2012-12-31 $84
2012-09-30 $78
2012-06-30 $79
2012-03-31 $92
2011-12-31 $53
2011-09-30 $63
2011-06-30 $71
2011-03-31 $44
2010-12-31 $61
2010-09-30 $58
2010-06-30 $66
2010-03-31 $75
2009-12-31 $82
2009-09-30 $26
2009-06-30 $32
2009-03-31 $39
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.061B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00